Seres Therapeutics (MCRB) vs NextCure (NXTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
NextCure is the larger company by market cap ($29.8 million vs $25.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | MCRB | NXTC |
|---|---|---|
| Share price | $2.52 | $6.51 |
| Market cap | $25.33M | $29.80M |
| 1-day change | -7.18% | -0.76% |
| YTD return | — | -53.77% |
| 1-year return | — | +7.07% |
| 5-year return | — | -93.74% |
| EPS (TTM) | $-2.42 | $-8.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $29.98 | $15.74 |
| 52-week low | $2.52 | $1.55 |
| Distance from 52-week high | -91.59% | -58.64% |
| Average volume | 72.00K | 2.11M |
| Shares outstanding | 10.04M | 4.58M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
MCRB vs NXTC FAQ
Which is bigger, Seres Therapeutics or NextCure?
NextCure (NXTC) is larger, with a market capitalization of $29.80M compared with $25.33M for Seres Therapeutics (MCRB).
Are Seres Therapeutics and NextCure in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.